Novartis Pharmaceuticals
Basel, Switzerland
NCT Number: NCT00219167
After a wash-out (1 to 2 weeks), and 2 to 4 week single-blind placebo run-in period, eligible patients will be randomized to receive lisinopril 10 mg, aliskiren 75 mg, 150 mg or 300 mg for a period of 8 weeks
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Phase 3
Basel, Switzerland
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Novartis
Industry
An 8-week, Randomized, Double-blind, Parallel-group, Multicenter Study Assessing the Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Patients With at Least 65 Years of Age With Essential Hypertension, Using 24-hour ABPM, With Lisinopril 10 mg as a Reference
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02055209
Cardiovascular Diseases, Hypertension
Bethesda, Maryland, United States
View Trial DetailsNCT02692846
Aortic Stenosis, Supravalvular, Aortic Valve Disease
Bethesda, Maryland, United States
View Trial DetailsNCT07747363
Cardiovascular Diseases, Chronic Disease
Austin, Texas, United States
View Trial DetailsNCT07432893
Body Temperature Changes, Breathlessness
Birbhum, West Bengal, India
View Trial Details